liu.seSök publikationer i DiVA
Ändra sökning
RefereraExporteraLänk till posten
Permanent länk

Direktlänk
Referera
Referensformat
  • apa
  • harvard1
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • oxford
  • Annat format
Fler format
Språk
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Annat språk
Fler språk
Utmatningsformat
  • html
  • text
  • asciidoc
  • rtf
Treatment of stage I seminoma, with one course of adjuvant carboplatin or surveillance, risk-adapted recommendations implementing patient autonomy: a report from the Swedish and Norwegian Testicular Cancer Group (SWENOTECA)
St Olavs University Hospital, Norway.
Skåne University Hospital, Sweden.
University of Bergen, Norway; Haukeland Hospital, Norway.
University of Tromso, Norway; University Hospital North Norway, Norway.
Visa övriga samt affilieringar
2016 (Engelska)Ingår i: Annals of Oncology, ISSN 0923-7534, E-ISSN 1569-8041, Vol. 27, nr 7, s. 1299-1304Artikel i tidskrift (Refereegranskat) Published
Resurstyp
Text
Abstract [en]

A total of 1118 patients with clinical stage I seminoma one course of adjuvant carboplatin or managed by surveillance were included. Stromal invasion of rete testis and tumor size amp;gt; 4 cm are confirmed as risk factors predicting relapse. Relapse rates following one course of adjuvant carboplatin is high and there is need to explore more effective adjuvant treatment options in patients with seminoma.The purpose of the protocol was to reduce the treatment burden in clinical stage I (CSI) seminoma by offering risk-adapted treatment. The protocol aimed to prospectively validate the proposed risk factors for relapse, stromal invasion of the rete testis and tumor diameter amp;gt; 4 cm, and to evaluate the efficacy of one course of adjuvant carboplatin. From 2007 to 2010, 897 patients were included in a prospective, population-based, risk-adapted treatment protocol implementing one course of adjuvant carboplatin AUC7 (amp;gt;n = 469) or surveillance (amp;gt;n = 422). In addition, results from 221 patients receiving carboplatin between 2004 and 2007 are reported. At a median follow-up of 5.6 years, 69 relapses have occurred. Stromal invasion of the rete testis [hazard ratio (HR) 1.9, amp;gt;P = 0.011] and tumor diameter amp;gt; 4 cm (HR 2.7, amp;gt;P amp;lt; 0.001) were identified as risk factors predicting relapse. In patients without risk factors, the relapse rate (RR) was 4.0% for patients managed by surveillance and 2.2% in patients receiving adjuvant carboplatin. In patients with one or two risk factors, the RR was 15.5% in patients managed by surveillance and 9.3% in patients receiving adjuvant carboplatin. We found no increased RR in patients receiving carboplatin amp;lt; 7 x AUC compared with that in patients receiving a parts per thousand yen7 x AUC. Stromal invasion in the rete testis and tumor diameter amp;gt; 4 cm are risk factors for relapse in CSI seminoma. Patients without risk factors have a low RR and adjuvant therapy is not justified in these patients. The efficacy of adjuvant carboplatin is relatively low and there is need to explore more effective adjuvant treatment options in patients with high-risk seminoma. The data do not support the concept of a steep dose response for adjuvant carboplatin.

Ort, förlag, år, upplaga, sidor
OXFORD UNIV PRESS , 2016. Vol. 27, nr 7, s. 1299-1304
Nyckelord [en]
testicular cancer; seminoma; surveillance; adjuvant carboplatin; risk-adapted; prognostic factors
Nationell ämneskategori
Kirurgi
Identifikatorer
URN: urn:nbn:se:liu:diva-130658DOI: 10.1093/annonc/mdw164ISI: 000379760700016PubMedID: 27052649OAI: oai:DiVA.org:liu-130658DiVA, id: diva2:954241
Anmärkning

Funding Agencies|Research Committee at St Olavs Hospital, Trondheim; Swedish Cancer Society; Swedish Association of Local Authorities and Regions; Norwegian Regional Health Authorities; Norwegian Urological Cancer Group

Tillgänglig från: 2016-08-22 Skapad: 2016-08-19 Senast uppdaterad: 2017-11-28

Open Access i DiVA

Fulltext saknas i DiVA

Övriga länkar

Förlagets fulltextPubMed

Personposter BETA

Wall, Najme

Sök vidare i DiVA

Av författaren/redaktören
Wall, Najme
Av organisationen
Avdelningen för kliniska vetenskaperOnkologiska kliniken USMedicinska fakulteten
I samma tidskrift
Annals of Oncology
Kirurgi

Sök vidare utanför DiVA

GoogleGoogle Scholar

doi
pubmed
urn-nbn

Altmetricpoäng

doi
pubmed
urn-nbn
Totalt: 50 träffar
RefereraExporteraLänk till posten
Permanent länk

Direktlänk
Referera
Referensformat
  • apa
  • harvard1
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • oxford
  • Annat format
Fler format
Språk
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Annat språk
Fler språk
Utmatningsformat
  • html
  • text
  • asciidoc
  • rtf